Alphatec Holdings is trading down 38.8% at $6.96 after third-quarter revenue missed expectations and management cut its 2026 outlook. - Its October 29, 2026, report showed third-quarter revenue of $221 million; the 2026 outlook fell to approximately $862 million from approximately $882 million. - Management cited weaker biologics attachment rates, softer procedure volumes and a temporary international supply constraint. - Analysts cut price targets as shares sharply underperformed the healthcare sector, which is up 2.32%.